C
112.00
1.18 (1.06%)
| Penutupan Terdahulu | 110.82 |
| Jumlah Dagangan | 185,057 |
| Harga / Pendapatan (P/E Ke hadapan) | 18.21 |
| Harga / Jualan (P/S) | 15.76 |
| Harga / Buku (P/B) | 16.98 |
| Julat 52 Minggu |
| Margin Keuntungan | 19.55% |
| Margin Operasi (TTM) | 2.17% |
| EPS Cair (TTM) | 1.15 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -26.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.00% |
| Nisbah Semasa (MRQ) | 3.07 |
| Aliran Tunai Operasi (OCF TTM) | 179.44 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 160.08 M |
| Pulangan Atas Aset (ROA TTM) | 9.18% |
| Pulangan Atas Ekuiti (ROE TTM) | 21.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Corcept Therapeutics Incorporat | Bercampur | Menurun |
AISkor Stockmoo
-0.6
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.60 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 11.49% |
| % Dimiliki oleh Institusi | 80.05% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LYON JOSEPH DOUGLAS | - | 110.43 | -72 | -7,951 |
| MADUCK SEAN | - | 110.43 | -117 | -12,920 |
| MOKARI ATABAK | - | 110.43 | -102 | -11,264 |
| ROBB GARY CHARLES | - | 110.43 | -91 | -10,049 |
| VIEIRA ROBERTO WANDENKOLK | - | 110.43 | -58,435 | -6,452,977 |
| Jumlah Keseluruhan Kuantiti Bersih | -58,817 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,495,161 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 110.43 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LYON JOSEPH DOUGLAS | Pegawai | 02 Sep 2026 | Dibuang (-) | 72 | 110.43 | 7,951 |
| VIEIRA ROBERTO WANDENKOLK | Pegawai | 02 Sep 2026 | Dibuang (-) | 102 | 110.43 | 11,264 |
| VIEIRA ROBERTO WANDENKOLK | Pegawai | 02 Sep 2026 | Jual automatik (-) | 58,333 | 110.43 | 6,441,713 |
| VIEIRA ROBERTO WANDENKOLK | Pegawai | 02 Sep 2026 | Pelaksanaan pilihan | 58,333 | - | - |
| ROBB GARY CHARLES | Pegawai | 02 Sep 2026 | Dibuang (-) | 91 | 110.43 | 10,049 |
| MOKARI ATABAK | Pegawai | 02 Sep 2026 | Dibuang (-) | 102 | 110.43 | 11,264 |
| MADUCK SEAN | Pegawai | 02 Sep 2026 | Dibuang (-) | 117 | 110.43 | 12,920 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |